Manages chronic stable angina (effort-associated angina). ANDA 215377, held by Pharmazone. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 215377 (Nicardipine Hydrochloride), held by Pharmazone, was first approved by FDA on Jul 17, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). Nicardipine hydrochloride capsules may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. Nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect (See DOSAGE AND ADMINISTRATION ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2023 | Original application | Approved | None posted |
| Nicardipine Hydrochloride20MG · capsule;oral | Nicardipine Hydrochloride | Rx |
| Nicardipine Hydrochloride30MG · capsule;oral | Nicardipine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters